Interaction of Meloxicam with cimetidine, Maalox, or aspirin
Interaction of Meloxicam with cimetidine, Maalox, or aspirin
复制标题
DOI：
10.1002/j.1552-4604.1996.tb04155.x
复制
发表时间：
1996-01-01
影响因子：
2.9
通讯作者：
Nehmiz, G
中科院分区：
文献类型：
--
作者：
Busch, U;Heinzel, G;Nehmiz, G
美洛昔康是一种新型的烯醇型羧胺类非甾体抗炎药。临床前研究表明，它具有较高的抗炎活性和较低的溃烂活性。这项开放、随机、交叉研究旨在考察阿司匹林、抗酸剂Maalox(德国科隆的罗恩-普伦克罗勒)和西咪替丁对健康男性志愿者单剂量口服美洛昔康30 mg的药代动力学和生物利用度的影响。测定美洛昔康的血药浓度，并进行非室药代动力学分析。美洛昔康耐受性良好，与西咪替丁或美洛昔康合用对美洛昔康的血药浓度-时间曲线、最大血药浓度(C-max)和血药浓度-时间曲线下面积(AUC(0-无穷))几乎没有影响。与阿司匹林同时治疗可增加美洛昔康的血浆浓度，使C-max增加约25%，AUC(0-无穷大)增加10%。这些差异不被认为与临床相关，美洛昔康剂量不应与阿司匹林、Maalox或西咪替丁合用而需要调整。
Meloxicam is a new enol carboxamide nonsteroidal antiinflammatory drug (NSAID). Preclinical studies have indicated that it possesses a high antiinflammatory potency and a low ulcerogenic potency. This open, randomized, crossover study was conducted to examine the effects of aspirin, the antacid Maalox (Rhone-Poulenc Rorer, Cologne, Germany), and cimetidine on the pharmacokinetics and bioavailability of a single oral dose of meloxicam 30 mg in healthy male volunteers. Plasma concentrations of meloxicam were determined and subjected to noncompartmental pharmacokinetic analysis. Meloxicam was well tolerated, and concomitant treatment with cimetidine or Maalox had little or no effect on the plasma concentration-time curves, maximum plasma concentration (C-max), or the area under the plasma concentration-time curve (AUC(0-infinity)) of meloxicam. Concurrent treatment with aspirin increased plasma concentrations of meloxicam, increasing C-max by approximately 25% and AUC(0-infinity) by 10%. These differences were not considered to be clinically relevant, and no adjustments of meloxicam dose should be required with coadministration of aspirin, Maalox, or cimetidine.